Evidence map›Paper›PMID 38023165›Full record

ArticleFrontiers in oncology2023

A multi-centric evaluation of self-learning GAN based pseudo-CT generation software for low field pelvic magnetic resonance imaging.

Jessica Prunaretty, Gorkem Güngör, Thierry Gevaert, David Azria, Simon Valdenaire, Panagiotis Balermpas, Luca Boldrini, Michael David Chuong, Mark De Ridder, Leo Hardy and 14 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 6 countries.

Jessica PrunarettyInstitut du Cancer de Montpellier, Department of Radiation Oncology, Montpellier, France.
Gorkem GüngörDepartment of Radiation Oncology, Maslak Hospital, Acibadem Mehmet Ali Aydınlar (MAA) University, Istanbul, Türkiye.
Thierry GevaertRadiotherapy Department, Universitair Ziekenhuis (UZ) Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
David AzriaInstitut du Cancer de Montpellier, Department of Radiation Oncology, Montpellier, France.
Simon ValdenaireInstitut du Cancer de Montpellier, Department of Radiation Oncology, Montpellier, France.
Panagiotis BalermpasDepartment of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Luca BoldriniRadiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Michael David ChuongDepartment of Radiation Oncology, Miami Cancer Institute, Miami, FL, United States.
Mark De RidderRadiotherapy Department, Universitair Ziekenhuis (UZ) Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Leo HardyTheraPanacea, Paris, France.
Sanmady KandibanTheraPanacea, Paris, France.
Philippe MaingonAssistance publique - Hôpitaux de Paris (AP-HP) Sorbonne Universite, Charles-Foix Pitié-Salpêtrière, Paris, France.
Kathryn Elizabeth MittauerDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, United States.
Enis OzyarDepartment of Radiation Oncology, Maslak Hospital, Acibadem Mehmet Ali Aydınlar (MAA) University, Istanbul, Türkiye.
Thais RoqueTheraPanacea, Paris, France.
Lorenzo ColomboTheraPanacea, Paris, France.
Nikos ParagiosTheraPanacea, Paris, France.
Ryan PennellRadiation Oncology, NewYork-Presbyterian/Weill Cornell Hospital, New York, NY, United States.
Lorenzo PlacidiRadiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Kumar ShreshthaTheraPanacea, Paris, France.
M P SpeiserRadiation Oncology Weill Cornell Medicine, New York, NY, United States.
Stephanie Tanadini-LangDepartment of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Vincenzo ValentiniRadiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Pascal FenogliettoInstitut du Cancer de Montpellier, Department of Radiation Oncology, Montpellier, France.
Institut de Recherche en Cancérologie de Montpellier · FRAgostino Gemelli University Polyclinic · ITUniversity Hospital of Zurich · CHVrije Universiteit Brussel · BEAcıbadem Adana Hospital · TRBaptist Hospital of Miami · USCornell University · USHôpital Charles-Foix · FRIstituti di Ricovero e Cura a Carattere Scientifico · ITKent Hastanesi · TRPresbyterian Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose/objectives: An artificial intelligence-based pseudo-CT from low-field MR images is proposed and clinically evaluated to unlock the full potential of MRI-guided adaptive radiotherapy for pelvic cancer care. Materials and method: In collaboration with TheraPanacea (TheraPanacea, Paris, France) a pseudo-CT AI-model was generated using end-to-end ensembled self-supervised GANs endowed with cycle consistency using data from 350 pairs of weakly aligned data of pelvis planning CTs and TrueFisp-(0.35T)MRIs. The image accuracy of the generated pCT were evaluated using a retrospective cohort involving 20 test cases coming from eight different institutions (US: 2, EU: 5, AS: 1) and different CT vendors. Reconstruction performance was assessed using the organs at risk used for treatment. Concerning the dosimetric evaluation, twenty-nine prostate cancer patients treated on the low field MR-Linac (ViewRay) at Montpellier Cancer Institute were selected. Planning CTs were non-rigidly registered to the MRIs for each patient. Treatment plans were optimized on the planning CT with a clinical TPS fulfilling all clinical criteria and recalculated on the warped CT (wCT) and the pCT. Three different algorithms were used: AAA, AcurosXB and MonteCarlo. Dose distributions were compared using the global gamma passing rates and dose metrics. Results: The observed average scaled (between maximum and minimum HU values of the CT) difference between the pCT and the planning CT was 33.20 with significant discrepancies across organs. Femoral heads were the most reliably reconstructed (4.51 and 4.77) while anal canal and rectum were the less precise ones (63.08 and 53.13). Mean gamma passing rates for 1%1mm, 2%/2mm, and 3%/3mm tolerance criteria and 10% threshold were greater than 96%, 99% and 99%, respectively, regardless the algorithm used. Dose metrics analysis showed a good agreement between the pCT and the wCT. The mean relative difference were within 1% for the target volumes (CTV and PTV) and 2% for the OARs. Conclusion: This study demonstrated the feasibility of generating clinically acceptable an artificial intelligence-based pseudo CT for low field MR in pelvis with consistent image accuracy and dosimetric results.

Indexed as

artificial intelligencecycle GANMRIpelvispseudo-CT

Identifiers

PMID38023165
PMCPMC10667706
OpenAlexW4388638614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.